An investigation for investors in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals was announced.
San Diego, CA -- (SBWIRE) -- 09/26/2018 -- An investigation was announced for investors of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals and certain of its directors and officers in connection with certain financial statements.
Investors who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Alnylam Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Cambrdige, MA based Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $47.16 million in 2016 to $89.91 million in 2017 and that its Net loss increased from $410.11 million in 2016 to $490.87 million in 2017.
On September 7, 2017, Alnylam Pharmaceuticals, Inc. advised investors that the Company had stop giving doses of fitusiran, Alnylam's experimental hemophilia treatment, to patients enrolled in the Company's clinical studies, following the death of a patient who developed a blood clot.
On September 12, 2018, Nomura/Instinet analyst Christopher Marai stated that a review document released by the U.S. Food and Drug Administration's ("FDA") Center for Drug Evaluation and Research "highlights greater risk" with respect to certain trials of Alnylams' ONPATTRO (patisiran) lipid complex injection, as well as "a limited market opportunity in TTRcardiomyopathy, and a potential platform safety risk." Specifically, Marai asserted that "[t]he document highlights FDA reviewers' concerns over cardiac deaths in patients treated with ONPATTRO and suggests that the drug should be limited to patients with polyneuropathy only (i.e., not patients with cardiac manifestations and polyneuropathy). Furthermore, we believe some comments on the lack of cardiac efficacy call into question claims made by [Alnylam] in this regard."
Those who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels